AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
2.970
-0.090 (-2.94%)
At close: Jul 19, 2024, 4:00 PM
3.000
+0.030 (1.01%)
Pre-market: Jul 22, 2024, 7:02 AM EDT
AbCellera Biologics Stock Forecast
ABCL's stock price has decreased by -62.64% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 16.5, with a low estimate of 5.00 and a high estimate of 24. The average target predicts an increase of 455.56% from the current stock price of 2.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ABCL stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +68.35% | Jul 11, 2024 |
| Keybanc | Keybanc | Buy Maintains $8 → $7 | Buy | Maintains | $8 → $7 | +135.69% | May 8, 2024 |
| Benchmark | Benchmark | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Feb 22, 2024 |
| Stifel | Stifel | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +472.39% | Feb 21, 2024 |
| Keybanc | Keybanc | Buy Initiates $6 | Buy | Initiates | $6 | +102.02% | Dec 5, 2023 |
Financial Forecast
Revenue This Year
42.32M
from 38.03M
Increased by 11.30%
Revenue Next Year
53.68M
from 42.32M
Increased by 26.84%
EPS This Year
-0.58
from -0.51
EPS Next Year
-0.63
from -0.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 56.3M | 72.1M | 160.2M | 215.8M | 100.7M |
| Avg | 42.3M | 53.7M | 90.2M | 121.7M | 91.7M |
| Low | 32.7M | 36.9M | 48.8M | 68.6M | 82.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.1% | 70.4% | 198.4% | 139.2% | -17.3% |
| Avg | 11.3% | 26.8% | 68.1% | 34.9% | -24.6% |
| Low | -13.9% | -12.7% | -9.1% | -24.0% | -32.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.55 | -0.44 | -0.40 | -0.23 | 0.02 |
| Avg | -0.58 | -0.63 | -0.62 | -0.22 | 0.02 |
| Low | -0.63 | -0.76 | -0.73 | -0.22 | 0.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.